This study is being done to answer the following questions: 1) Can the study drug iberdomide be given after idecabtagene vicleucel (ide-cel (Abecma)) CAR-T in multiple myeloma safely and with acceptably few and mild side effects? 2) For how long does multiple myeloma stay under control (in remission) if patients receive the study drug iberdomide after they have received ide-cel (Abecma) CAR-T? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your multiple myeloma. The usual approach is defined as care most people get for multiple myeloma.
The following tests and procedures will be done on this study: medical history review, full or symptom-directed physical, pulse, blood pressure, weight, adverse event assessment, patient medication diary review, pregnancy prevention counseling, Iberdomide dispensing, complete blood count (CBC) with differential, complete metabolic profile, blood lactate dehydrogenase and beta-2-microglobulin, serum HCG, serum protein electrophoresis, serum immunofixation quantitative immunoglobulins, serum free light chains, 24 hour urine protein electrophoresis and immunofixation, bone marrow biopsy and aspirate, CT/MRI/PET scans, tissue and blood samples for correlative studies.
You or your insurance provider will not have to pay for the iberdomide while you take part in this study.
NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA
UNC Hospitals Hillsborough Campus
460 Waterstone Dr, Hillsborough, NC 27278, USA
Sascha Tuchman
LCCC - Clinical Trials
Clinical or Medical
Interventional
Blood Conditions
Cancer (Multiple Myeloma)
24-1088